---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-005754"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2022-04-18T23:59:59+00:00"
generated_at: "2026-06-26T06:55:28.956659+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics to acquire Inform Diagnostics for $170M; prelim Q1 revenue ~$300M, above guidance

## Summary
- Acquisition of Inform Diagnostics for ~$170M cash; expected to close Q2 2022, funded from cash on hand.
- Preliminary Q1 total revenue ~$300M, exceeding prior guidance of $245M; core rev excl. COVID at least $22M.
- FY2022 core revenue guidance raised to ~$175M from $120M, including expected acquisition contribution.
- Acquisition adds pathology services (GI, derm, heme, etc.), 1,300 clients, 2,700 physicians, 300M+ covered lives.
- Transaction expected to contribute to core revenue and be accretive to pro forma EBITDA.

## SEC filing metadata
- accession: 0000950170-22-005754
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2022-04-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000095017022005754/0000950170-22-005754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000095017022005754/flgt-20220416.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-005754
- JSON: https://secwatch.observer/filing/0000950170-22-005754.json
- Plain text: https://secwatch.observer/filing/0000950170-22-005754.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.